Stock Movers: Goldman Sachs Earnings, Apple Tariffs, Pfizer Drug Pivot, Intel Stake Sale

Goldman Sachs Earnings and Buyback

• 📈 Goldman Sachs shares rose significantly, driven by strong first-quarter earnings.
• 💰 The bank reported its highest quarterly revenue haul on record, with a 27% increase in equities trading revenue year-over-year.
• 🏦 A major announcement was the approval of a $40 billion share buyback program, representing 25.2% of its market cap.
• 🗣️ CEO David Solomon expressed confidence in supporting clients despite a changing operating environment.

Apple and Tariff Relief

• 🍎 Apple shares saw a notable increase, benefiting from news of exemptions on certain tech products from tariffs.
• ⚠️ The tariff situation was complex, with initial White House exemptions later described as temporary by President Trump.
• 🌐 The positive impact extended to other tech companies like Dell and HP, as well as chip sector giants such as Nvidia, AMD, Broadcom, and Qualcomm.
• 🌏 Apple suppliers in Asia, including Foxconn, also experienced gains, closing up around 3%.

Pfizer's Obesity Pill Setback

• 💊 Pfizer announced it will stop development on its obesity pill, danuglipron, due to a potential drug-related liver injury in a clinical trial patient.
• 📉 This decision is a significant blow, as Pfizer was already trailing competitors in the lucrative obesity market.
• 🚀 The company plans to shift its focus to earlier-stage obesity treatments.
• 🤝 Competitors Novo Nordisk and Eli Lilly saw their shares rise, with Novo Nordisk ADRs up about 3% and Eli Lilly shares up as much as 2%.

Intel's Strategic Stake Sale

• ⚡ Intel shares are soaring amid news of a pause in US tariffs on chips and tech.
• 🤝 Intel is nearing an agreement to sell a 51% stake in its programmable chips unit, Altera, to Silver Lake Management.
• 💰 This deal values Altera at $8.75 billion, a notable decrease from Intel's 2015 acquisition price of approximately $17 billion.
• 🎯 The move is part of Intel's strategy to spin off non-core businesses and assets as it navigates market share losses and the evolving AI accelerator landscape.